Compare Davita Inc (DVA) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nucor Corporation — how do they compare? Davita Inc trades at $179.08 (market cap $11.43B), while Nucor Corporation trades at $272.6 (market cap $61.78B). The key difference: Nucor Corporation is far larger — about 5.4× Davita Inc's market cap, and Nucor Corporation pays a 0.82% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | NUE | |
|---|---|---|
Market Cap | $11.43B | $61.78B |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $274.74 |
52-Week Low | $103.87 | $131.78 |
Enterprise Value | $24.15B | $66.18B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.17, showing modest daily gains of 0.47% amid bearish technical signals. The stock demonstrates strong fundamental performance with consistent earnings beats (Q2 2026 EPS of $4.02 vs. $3.88 expected) and attractive valuation metrics including P/E of 15.38 and P/S of 0.91. Recent news highlights volume growth momentum but concerns about narrowing margins and reimbursement pressures. Analyst consensus remains positive with a $232.25 price target representing 30% upside potential from current levels.
The outlook remains cautiously optimistic given DVA's strong earnings track record and institutional support, though investors face risks from reimbursement pressure, high debt levels (debt-to-asset ratio of 65.55% in 2025), and mixed technical indicators. The stock's current valuation presents opportunity if margin pressures ease and volume growth continues as projected through 2026.
Nucor Corporation (NUE) trades at $272.29, showing modest 0.13% daily gains amid strong technical momentum. The stock maintains bullish technical signals with recent Q2 2026 earnings beating estimates at $4.84 EPS versus $4.46 expected. Revenue trends show recovery from 2024 lows, with 2026 projections indicating improved profitability. The company continues strategic expansion with a $59 million investment in its Indiana facility announced August 13, 2026.
Nucor presents a balanced investment case with analyst consensus favoring bullish sentiment (59% buy ratings) and a $279.63 price target offering modest upside. Strong earnings momentum and operational improvements support growth prospects, though cyclical steel industry exposure and margin pressures from input costs remain key risks. The stock's current valuation at 21.69 P/E appears reasonable given recovery trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
